Payment overview · 2025
General Payments
$50.01
2 reported records · 2 companies
Healthcare provider profile · identity verified
Mario E Cote, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SPRING VALLEY, IL · NPI 1376514273
Verified facts
What the public records show
CMS Open Payments records show Mario E Cote, M.D. received $50.01 in general payments during 2025 across 2 reported records.
Novartis Pharmaceuticals Corporation accounted for 63.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $31.92 | 63.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.09 | 36.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $50.01 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $31.92 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 981 | 293 |
| Levothyroxine Sodium | Levothyroxine Sodium | 755 | 201 |
| Amlodipine Besylate | Amlodipine Besylate | 667 | 179 |
| Lisinopril | Lisinopril | 585 | 170 |
| Metformin Hcl | Metformin Hcl | 572 | 159 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 524 | 162 |
| Eliquis | Apixaban | 437 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 406 | 122 |
| Metoprolol Succinate | Metoprolol Succinate | 382 | 107 |
| Losartan Potassium | Losartan Potassium | 370 | 102 |
| Omeprazole | Omeprazole | 337 | 105 |
| Hydrochlorothiazide | Hydrochlorothiazide | 320 | 90 |
| Gabapentin | Gabapentin | 317 | 79 |
| Tramadol Hcl | Tramadol Hcl | 304 | 74 |
| Pravastatin Sodium | Pravastatin Sodium | 273 | 77 |
| Furosemide | Furosemide | 271 | 89 |
| Jardiance | Empagliflozin | 267 | 58 |
| Potassium Chloride | Potassium Chloride | 253 | 83 |
| Simvastatin | Simvastatin | 252 | 70 |
| Allopurinol | Allopurinol | 244 | 61 |
| Sertraline Hcl | Sertraline Hcl | 229 | 65 |
| Metoprolol Tartrate | Metoprolol Tartrate | 205 | 65 |
| Lorazepam | Lorazepam | 193 | 57 |
| Alendronate Sodium | Alendronate Sodium | 190 | 59 |
| Valsartan | Valsartan | 156 | 49 |
| Alprazolam | Alprazolam | 144 | 36 |
| Rybelsus | Semaglutide | 143 | 27 |
| Warfarin Sodium | Warfarin Sodium | 142 | 37 |
| Ozempic | Semaglutide | 136 | 27 |
| Carvedilol | Carvedilol | 130 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 130 | 36 |
| Irbesartan | Irbesartan | 125 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 125 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 124 | 31 |
| Ezetimibe | Ezetimibe | 117 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 115 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 112 | 40 |
| Atenolol | Atenolol | 112 | 31 |
| Farxiga | Dapagliflozin Propanediol | 112 | 26 |
| Donepezil Hcl | Donepezil Hcl | 110 | 33 |
| Mirtazapine | Mirtazapine | 100 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 100 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 30 |
| Spironolactone | Spironolactone | 94 | 29 |
| Prednisone | Prednisone | 87 | 50 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 85 | 17 |
| Trazodone Hcl | Trazodone Hcl | 84 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 82 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 82 | 13 |
| Mounjaro | Tirzepatide | 77 | 21 |
| Glipizide | Glipizide | 76 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 21 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 73 | 29 |
| Glimepiride | Glimepiride | 71 | 20 |
| Xarelto | Rivaroxaban | 69 | 17 |
| Pregabalin | Pregabalin | 68 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 64 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 13 |
| Montelukast Sodium | Montelukast Sodium | 59 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 57 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 40 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | 17 |
| Klor-Con M20 | Potassium Chloride | 53 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 53 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 13 |
| Famotidine | Famotidine | 49 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 13 |
| Sucralfate | Sucralfate | 45 | 15 |
| Synthroid | Levothyroxine Sodium | 45 | 16 |
| Chlorthalidone | Chlorthalidone | 44 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 44 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 44 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | suppressed |
| Clonazepam | Clonazepam | 42 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 41 | 11 |
| Propranolol Hcl | Propranolol Hcl | 41 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 39 | 13 |
| Meloxicam | Meloxicam | 39 | 17 |
| Memantine Hcl | Memantine Hcl | 38 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 35 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 32 | 14 |
| Metformin Hcl Er | Metformin Hcl | 32 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 31 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 31 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 31 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 31 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 29 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 29 | 12 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 29 | 15 |
| Amoxicillin | Amoxicillin | 28 | 21 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 28 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Trandolapril | Trandolapril | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 16 |
| Topiramate | Topiramate | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Azithromycin | Azithromycin | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 20 | 16 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Nadolol | Nadolol | 18 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Verapamil Sr | Verapamil Hcl | 18 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $50.01 · 2 records | Novartis Pharmaceuticals Corporation | EVENITY, LEQVIO | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novartis Pharmaceuticals Corporation?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error